Eine Studie, um mehr über die Veränderung der Blutspiegel von Transthyretin zu erfahren, wenn Teilnehmer mit Transthyretin-Amyloidose mit Kardiomyopathie von Tafamidis auf Acoramidis umstellen (ACO-SWITCH)
Eine prospektive, einarmige Phase-4-Studie zur Bewertung des Verlaufs des Serum-Transthyretin (TTR)-Spiegels mit Acoramidis bei erwachsenen Patienten mit variabler oder Wildtyp-Transthyretin-Amyloidose mit Kardiomyopathie (ATTR-CM), die zuvor mit Tafamidis behandelt wurden
Transthyretin (TTR) is a protein made by the liver that helps transport thyroid hormone and vitamin A in the blood. In some people, this protein breaks down and forms harmful clumps called amyloid. TTR amyloid gets deposited in the heart wall and stops it from pumping blood properly, which may lead to heart failure. The breakage in TTR protein can be age-related (wild-type ATTR-CM), or genetic (variant ATTR-CM).
The study drug, acoramidis, works by attaching itself to the TTR protein, making TTR more stable and less likely to break down and form amyloid (clumps). This helps to slow down the progression of the disease, improve heart function, and increase the TTR levels in the blood. Acoramidis is an approved treatment for wild-type or variant ATTR-CM in Europe and the United States.
Tafamidis is another drug that stabilizes TTR and prevents it from breaking down.
In this study, acoramidis will be studied in participants with ATTR--CM who were previously treated with tafamidis. The main purpose of this study is to assess the change in blood TTR levels after participants are switched from tafamidis to acoramidis. This will be studied to understand if acoramidis causes an increase in blood TTR levels beyond the levels achieved with tafamidis.
For this, the researchers will measure the change in the levels of TTR protein in participants' blood after 6 months of the treatment with acoramidis, or earlier if a participant stops the treatment before reaching that six-month mark.
All participants will continue taking tafamidis during the screening period. In the treatment period of the study, participants will take acoramidis as two tablets twice daily by mouth, for up to 6 months.
At the start of this study, the study doctors will review each participant's medical history and check their overall health. The study doctors will perform electrocardiograms (ECG), and measure blood pressure and heart rate. Researchers will also take blood and urine samples from the participants to measure levels of TTr, NT-proBNP, hs-TnT, hs-CRP, RBP4, eGFR, creatinine, cystatin-C, UACR, and TSH at the start of the study, and at various time points thereafter (during the study) to assess heart, kidney and thyroid function.
There will be a total of 9 study check-ins. Participants will visit the study site twice: at screening and at the end of treatment period. A study nurse will visit the participant's home 6 times, at the start of treatment, Weeks 1, 2, 3 and 4, then again at 3 months. The final check-in will be done by phone.
The study doctors will monitor the health of the participants regularly for any medical problems during follow-up visits. Participants will know the treatment they will receive during the study. Each participant could be in the study for about 8 months.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 4
Kontakte und Standorte
Studienkontakt
- Name: Bayer Clinical Trials Contact
- Telefonnummer: 18888422937
- E-Mail: clinical-trials-contact@bayer.com
Studienorte
-
-
Brussels Capital
-
Brussels, Brussels Capital, Belgien, 1070
- Noch keine Rekrutierung
- Hôpital Erasme/Erasmus Ziekenhuis
-
-
West Flanders
-
Bruges, West Flanders, Belgien, 8000
- Noch keine Rekrutierung
- AZ St-Jan Brugge-Oostende A.V.
-
-
-
-
-
Berlin, Deutschland, 10365
- Zurückgezogen
- Sana Klinikum Lichtenberg - Klinik für Innere Medizin II, Schwerpunkt Kardiologie
-
Hamburg, Deutschland, 20246
- Zurückgezogen
- Universitätsklinikum Hamburg Eppendorf (UKE)-Universitären Herz- und Gefäßzentrum Hamburg, Klinik für Kardiologie
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Deutschland, 89081
- Zurückgezogen
- Universitaetsklinikum Ulm | Klinik fuer Innere Medizin II
-
-
Hesse
-
Darmstadt, Hesse, Deutschland, 64287
- Noch keine Rekrutierung
- KVZ Kardiovaskulaeres Zentrum Darmstadt GmbH
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Deutschland, 17475
- Zurückgezogen
- Universitaetsmedizin Greifswald KöR- Klinik und Poliklinik für Innere Medizin B
-
-
North Rhine-Westphalia
-
Bonn, North Rhine-Westphalia, Deutschland, 53127
- Zurückgezogen
- Universitätsklinikum Bonn - Herzzentrum des Universitätsklinikums Bonn
-
-
-
-
-
Naples, Italien, 80131
- Noch keine Rekrutierung
- Azienda Ospedaliera Dei Colli_Monaldi - Malattie Rare e Genetiche Cardiovascolari
-
-
Apulia
-
Lecce, Apulia, Italien, 73100
- Noch keine Rekrutierung
- Ospedale Vito Fazzi Lecce_Cardiologia e UTIC
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italien, 40138
- Noch keine Rekrutierung
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS_Policlinico Sant'Orsola_Cardiologia
-
-
Lombardy
-
Bergamo, Lombardy, Italien, 24127
- Rekrutierung
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII - Cardiologia 1
-
Milan, Lombardy, Italien, 20138
- Rekrutierung
- Centro Cardiologico Monzino S.p.A. - Cardiologia Peri-Operatoria e Imaging Cardiovascolare
-
Pavia, Lombardy, Italien, 27100
- Noch keine Rekrutierung
- Fondazione IRCCS Policlinico San Matteo-SC Medicina Generale 2 - Centro Amiloidosi Sistemiche e Malattie ad Alta Complessità
-
-
Tuscany
-
Florence, Tuscany, Italien, 50134
- Rekrutierung
- Careggi University Hospital_cardio intensive care unit
-
Pisa, Tuscany, Italien, 56124
- Rekrutierung
- Fondazione Toscana Gabriele Monasterio_Pisa - Cardiologia e Medicina Cardiovascolare
-
Siena, Tuscany, Italien, 53100
- Rekrutierung
- Azienda Ospedaliera Universitaria Senese - cardiologia
-
-
Veneto
-
Padova, Veneto, Italien, 35128
- Rekrutierung
- Azienda Ospedale-Università di Padova-UOC Cardiologia
-
-
-
-
-
Oslo, Norwegen, 0424
- Noch keine Rekrutierung
- Oslo Universitetssykehus HF, Rikshospitalet
-
-
-
-
Lower Austria
-
Sankt Pölten, Lower Austria, Österreich, 1210
- Zurückgezogen
- Universitätsklinikum St. Pölten - Lilienfeld - Klinische Abteilung für Innere Medizin 3
-
-
State of Vienna
-
Vienna, State of Vienna, Österreich, 3500
- Noch keine Rekrutierung
- Klinik Ottakring - 3. Medizinische Abteilung mit Kardiologie, internistischer Intensivmedizin und Ambulanz
-
Vienna, State of Vienna, Österreich, 1090
- Rekrutierung
- Medizinische Universität Wien- Universitätsklinik für Innere Medizin II, Klinische Abteilung für Kardiologie
-
Vienna, State of Vienna, Österreich, 1100
- Rekrutierung
- Klinik Favoriten - 5.Medizinische Abteilung-Kardiologie
-
-
Styria
-
Vienna, Styria, Österreich, 1030
- Rekrutierung
- Medizinische Universität Graz- Klinische Abteilung für Kardiologie
-
-
Upper Austria
-
Braunau am Inn, Upper Austria, Österreich, 5280
- Rekrutierung
- Krankenhaus St. Josef Braunau | Innere Medizin I
-
-
Vorarlberg
-
Feldkirch, Vorarlberg, Österreich, 6800
- Zurückgezogen
- VIVIT - Landeskrankenhaus Feldkirch - Innere Medizin I, Kardiologie, Angiologie, Endokrinologie, Diabetologie, Intensivmedizin
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Participants must be 18 to 90 years of age inclusive, at the time of signing the informed consent.
- Diagnosis of ATTR-CM; disease defining examination, i.e., Single Photon Emission Computed Tomography (SPECT) or SPECT/Computed Tomography (CT) or biopsy, within 24 months prior to Visit 1 (V1).
- Participants must currently be treated with tafamidis and have used tafamidis for at least the previous 3 months prior to V1 and have adhered to tafamidis therapy.
- New York Heart Association (NYHA) class ≤ II at V1.
- Estimate glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m^2 at V1.
- N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) > 300 and ≤ 7000 pg/mL at V1.
Exclusion Criteria:
- Prior liver or heart transplantation or planned within the next 12 months.
- Current or planned use of ventricular assist device.
- Active cancer or other disease that decreases the life expectancy to less than one year.
- Heart failure due to ischemic heart disease.
- Myocardial infarction, cardiovascular (CV) surgery, or unstable angina within the last 90 days prior to V1.
- Confirmed diagnosis of light-chain amyloidosis.
- Dialysis or severe renal impairment as reflected by Urinary Albumin Creatinine Ratio (UACR) > 300 mg/g at V1.
- Major surgery within 90 days prior to V1.
- Recent initiation of Sodium-Glucose-Cotransporter-2 inhibitors (SGLT2i) within 3 months before V1.
- Initiation of treatment with a diuretic or increase in diuretic dose within 3 months before V1.
- Treatment with calcium channel blockers (e.g., verapamil, diltiazem) or digitalis.
- Recent CV hospitalization within 3 months before V1.
- Known hypersensitivity to acoramidis or to any of the excipients.
- A condition that, as judged by the investigator, would preclude compliance with the study protocol, such as a history of substance abuse, alcoholism, or a psychiatric condition.
- Known or suspected liver disorder and bile secretion/flow (cholestasis, also history of it).
- Abnormal liver function tests at V1, defined as ALT (GPT) or AST (GOT) ≥ 3 x ULN or total bilirubin ≥ 3 x ULN at V1.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Acoramidis
Participants will receive acoramidis 712 mg orally BID |
356 mg film-coated tablets. The recommended dose of acoramidis is 712 mg (two tablets, 356 mg) orally, twice daily, corresponding to a total daily dose of 1424 mg.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in serum TTR level from baseline to month 6 or premature discontinuation of treatment
Zeitfenster: From baseline to month 6 or premature discontinuation of treatment
|
TTR = Transthyretin |
From baseline to month 6 or premature discontinuation of treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der Teilnehmer mit TEAEs und schwerwiegenden TEAEs
Zeitfenster: Von der ersten Verabreichung des Prüfpräparats bis 30 Tage nach der letzten Dosis des Prüfpräparats oder Studienende, je nachdem, was zuerst eintritt
|
Von der ersten Verabreichung des Prüfpräparats bis 30 Tage nach der letzten Dosis des Prüfpräparats oder Studienende, je nachdem, was zuerst eintritt
|
|
|
Änderung von Baseline bis Monat 6 bei Kreatinin
Zeitfenster: Von der Basislinie bis zum Monat 6
|
Von der Basislinie bis zum Monat 6
|
|
|
Veränderung von Baseline zu Monat 6 in Cystatin C
Zeitfenster: Von der Baseline bis zum Monat 6
|
Von der Baseline bis zum Monat 6
|
|
|
Change in serum TTR level from baseline to week 1, 2, 3, 4 and at month 3.
Zeitfenster: At baseline, week 1, 2, 3, 4 and at month 3
|
TTR = Transthyretin |
At baseline, week 1, 2, 3, 4 and at month 3
|
|
Change from baseline to month 6 of NT-proBNP
Zeitfenster: From baseline to month 6
|
NT-proBNP = N-terminal pro-B-type Natriuretic Peptide |
From baseline to month 6
|
|
Change from baseline to month 6 of hs-TnT
Zeitfenster: From baseline to month 6
|
hs-TNT = high-sensitivity Troponin T |
From baseline to month 6
|
|
Change from baseline to month 6 of RBP4
Zeitfenster: From baseline to month 6
|
RBP4 = Retinol Binding Protein 4 |
From baseline to month 6
|
|
Signs of cardiac remodeling from baseline to month 6
Zeitfenster: From baseline to month 6
|
These signs will be measured by echocardiogram |
From baseline to month 6
|
|
Change from baseline to month 6 in 6MWD
Zeitfenster: From baseline to month 6
|
The 6-Minute Walk distance (6MWD) measures the total distance that a participant could walk in 6 minutes. |
From baseline to month 6
|
|
Change from baseline to month 6 in the eGFR
Zeitfenster: From baseline to month 6
|
eGFR = estimated glomerular filtration rate |
From baseline to month 6
|
|
Change from baseline to month 6 in UACR
Zeitfenster: From baseline to month 6
|
UACR = Urinary Albumin Creatinine Ratio |
From baseline to month 6
|
|
Change from baseline to month 6 in TSH
Zeitfenster: From baseline to month 6
|
TSH = Thyroid Stimulating Hormone |
From baseline to month 6
|
|
Change from baseline to month 6 in KCCQ-OS score
Zeitfenster: From baseline to month 6
|
The Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) is 23-item questionnaire developed to measure health status and health-related quality of life (QoL) in individuals with heart failure. Items include heart failure symptoms, impact on physical and social functions, and how heart failure impacts QoL. |
From baseline to month 6
|
|
Change from baseline to month 6 of EQ-5D-5L index score
Zeitfenster: From baseline to month 6
|
The EuroQol-5-Dimension-5-Level (EQ-5D-5L) includes two parts. In the first part, participants are asked to rate their current health state on 5 dimensions (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having five levels of function (1-no problem, 2-slight problem, 3-moderate problem, 4-severe problem, and 5-extreme problem). The second part is a self-rating of current health status on a Visual Analogue Scale (EQ VAS) with endpoints labeled "best imaginable health state" (score of 100) and "worst imaginable health state" (score of 0). The scores from the 5 dimensions are used to calculate the index score. |
From baseline to month 6
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 23026
- 2025-521831-35-00 (Registrierungskennung: CTIS (EU))
- 2025 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access.
As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .